Trials / Withdrawn
WithdrawnNCT03336372
Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients
- Status
- Withdrawn
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Center for Clinical Studies, Texas · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients at least 18 years of age will be enrolled in the study to assess the efficacy and tolerability of Picato gel in the treatment of molluscum contagiosum. Patients must have an immunocompromised condition due to taking immunosuppressive drugs or having an inherited disease affecting the immune system.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Picato | Picato 0.05% or 0.015% topical gel applied nightly for 3 consecutive nights |
Timeline
- Start date
- 2017-12-20
- Primary completion
- 2018-09-08
- Completion
- 2018-10-16
- First posted
- 2017-11-08
- Last updated
- 2022-04-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03336372. Inclusion in this directory is not an endorsement.